Montelukast induced acute hepatocellular liver injury
A 46-year-old male with uncontrolled asthma on inhaled albuterol and formoterol with budesonide was commenced on montelukast. He developed abdominal pain and jaundice 48 days after initiating montelukast therapy. His liver tests showed an increase in serum total bilirubin, conjugated bilirubin, aspa...
Saved in:
Published in | Journal of postgraduate medicine Vol. 55; no. 2; pp. 141 - 142 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
India
Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
01.04.2009
Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A 46-year-old male with uncontrolled asthma on inhaled albuterol and
formoterol with budesonide was commenced on montelukast. He developed
abdominal pain and jaundice 48 days after initiating montelukast
therapy. His liver tests showed an increase in serum total bilirubin,
conjugated bilirubin, aspartate aminotranferase, alanine
aminotranferase, and alkaline phosphatase. The patient was evaluated
for possible non-drug related liver injury. Montelukast was
discontinued suspecting montelukast induced hepatocellular liver
injury. Liver tests began to improve and returned to normal 55 days
after drug cessation. Causality of this adverse drug reaction by the
Council for International Organizations of Medical Sciences or Roussel
Uclaf Causality Assessment Method (CIOMS or RUCAM) and Naranjo′s
algorithm was ′probable′. Liver tests should be monitored
in patients receiving montelukast and any early signs of liver injury
should be investigated with a high index of suspicion for drug induced
liver injury. |
---|---|
ISSN: | 0022-3859 0972-2823 |
DOI: | 10.4103/0022-3859.52850 |